[ Pobierz całość w formacie PDF ]

14. Patro SY, Freund E, Chang BS. 2002. Protein
formulation and fill-finish operations. Biotechnol
Annu Rev 8:55 84.
15. Manning MC, Patel K, Borchardt RT. 1989. Stabi-
lity of protein pharmaceuticals. Pharm Res 6:903
1. Glenny A, Buttle G, Stevens M. 1931. Rate of dis- 918.
appearance of diphtheria toxoid injected into rab- 16. Davies MJ. 2003. Singlet oxygen-mediated damage
bits and guinea-pigs: Toxoid precipitated with to proteins and its consequences. Biochem Biophys
alum. J Pathol Bacteriol 34:267 275. Res Commun 305:761 770.
2. Eldridge J, Staas J, Mueulbroek A, Tice T, Gilley R. 17. Schoneich C, Sharov VS. 2006. Mass spectrometry
1991. Biodegradable and biocompatible poly(DL- of protein modifications by reactive oxygen and
Lactide-Co-Glycolide) microspheres as an adjuvant nitrogen species. Free Rad Biol Med 41:1507 1520.
for staphylococcal enterotoxin B toxoid which 18. Thirumangalathu R, Krishnan S, Bondarenko P,
enhances the level of toxin-neutralizing antibodies. Speed-Ricci M, Randolph TW, Carpenter JF, Brems
Infect Immunol 59:2978 2986. DN. 2007. Oxidation of methionine residues in
3. Gupta R, Rost B, Releveld E, Siber G. 1995. Adju- recombinant human interleukin-1 receptor antago-
vant properties of aluminum and calcium com- nist: Implications of conformational stability on
pounds. In: Powel M, Newman M, editors. protein oxidation kinetics. Biochemistry 46:6213
Pharmaceutical biotechnology. New York: Plenum 6224.
Press. pp. 229 248. 19. Nilsson MR, Driscoll M, Raleigh DP. 2002. Low
4. Byrne M, Smith L. 2000. Development of vaccines levels of asparagine deamidation can have a dra-
for prevention of botulism. Biochimie 82:955 966. matic effect on aggregation of amyloidogenic pep-
5. O Hagan D, MacKichan M, Singh M. 2001. Recent tides: Implications for the study of amyloid
developments in adjuvants for vaccines against formation. Protein Sci 11:342 349.
infectious diseases. Biomol Eng 18:69 85. 20. Flaugh SL, Mills IA, King J. 2006. Glutamine dea-
6. Singh M, O Hagan D. 1999. Advances in vaccine midation destabilizes human gammaD-crystallin
adjuvants. Nat Biotechnol 17:1075 1081. and lowers the kinetic barrier to unfolding. J Biol
7. McInerny T, Brennan F, Jones T, Dimmock N. Chem 281:30782 30793.
1999. Analysis of the ability of five adjuvants to 21. Jones LS, Peek LJ, Power J, Markham A, Yazzie B,
enhance immune response to a chimeric plant virus Middaugh CR. 2005. Effects of adsorption to alu-
displaying an HIV-1 peptide. Vaccine 17:1359 minum salt adjuvants on the structure and stability
1368. of model protein antigens. J Biol Chem 280:13406
8. Rinella J, Workman R, Hermodson M, White J, 13414.
Hem S. 1998. Elutability of proteins form alumi- 22. Wittayanukulluk A, Jiang D, Regnier FE, Hem SL.
num-containing vaccine adjuvants by treatment of 2004. Effect of microenvironment pH of aluminum
surfactants. J Colloid Interf Sci 197:48 56. hydroxide adjuvant on the chemical stability of
9. Jendrick S, Little S, Hem S, Mitra G, D Giardina S. adsorbed antigen. Vaccine 22:1172 1176.
2003. Evaluation of the compatibility of a second 23. Volkin DB, Sanyal G, Burke CJ, Middaugh CR.
generation recombinant anthrax vaccine with 2002. Preformulation studies as an essential guide
aluminum-containing adjuvants. Vaccine 21:3011 to formulation development and manufacture of
3018. protein pharmaceuticals. In: Nail SL, Akers MJ,
10. Lindblad E. 2004. Aluminum adjuvants In retro- editors. Pharmaceutical biotechnology. New York:
spect and prospect. Vaccine 22:3658 3668. Kluwer Academic. p. 1 46.
11. DePaz RA, Henderson I, Advant S. 2005. Formula- 24. Chang BS, Hershenson S. 2002. Practical
tion of botulinum neurotoxin heavy chain frag- approaches to protein formulation development.
ments for vaccine development: Mechanisms of Pharm Biotechnol 13:1 25.
adsorption to an aluminum-containing adjuvant. 25. Lehmann WD, Schlosser A, Erben G, Pipkorn R,
Vaccine 23:4029 4035. Bossemeyer D, Kinzel V. 2000. Analysis of isoas-
partate in peptides by electrospray tandem mass 29. Simpson LL. 2004. Identification of the major steps
spectrometry. Protein Sci 9:2260 2268. in botulinum toxin action. Ann Rev Pharmacol
26. Larsen MR, Trelle MB, Thingholm TE, Jensen ON. Toxicol 44:167 193.
2006. Analysis of posttranslational modifications of 30. Rosenberg JS, Middlebrook JL, Atassi MZ. 1997.
proteins by tandem mass spectrometry. Biotechni- Localization of the regions on the C-terminal
ques 40:790 798. domain of the heavy chain of botulinum toxin A
27. Stadtman ER, Van Remmen H, Richardson A, recognized by T lymphocytes and by antibodies
Wehr NB, Levine RL. 2005. Methionine oxidation after immunization of mice with pentavalent toxid.
and aging. Biochim Biophys Acta 1703:135 140. Immun Invest 26:491 504.
28. Rummel A, Eichner T, Weil T, Karnath T, Gutcaits 31. Kubota T, Watanabe T, Yokosawa N, Tsuzuki K,
A, Mahrhold S, Sandhoff K, Proia RL, Acharya KR, Indoh T, Moriishi K, Sanda K, Maki Y, Inoue K,
Bigalke H, Binz T. 2007. Identification of the pro- Fujii N. 1997. Epitope regions in the heavy chain of
tein receptor binding site of botulinum neurotoxins Clostridium botulinum type E neurotoxin recog-
B and G prove the double-receptor concept. Proc nized by monoclonal antibodies. Appl Environ
Natl Acad Sci 104:359 364. Microbiol 63:1214 1218.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 98, NO. 9, SEPTEMBER 2009 DOI 10.1002/jps [ Pobierz całość w formacie PDF ]